Brokerages Expect Haemonetics Co. (NYSE:HAE) to Post $0.60 EPS

Analysts expect Haemonetics Co. (NYSE:HAEGet Rating) to announce $0.60 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Haemonetics’ earnings, with estimates ranging from $0.57 to $0.62. Haemonetics reported earnings of $0.46 per share during the same quarter last year, which would indicate a positive year over year growth rate of 30.4%. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Haemonetics will report full-year earnings of $2.53 per share for the current year, with EPS estimates ranging from $2.50 to $2.55. For the next fiscal year, analysts forecast that the company will post earnings of $2.76 per share, with EPS estimates ranging from $2.55 to $3.05. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Haemonetics.

Haemonetics (NYSE:HAEGet Rating) last issued its quarterly earnings data on Tuesday, February 8th. The medical instruments supplier reported $0.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.09. Haemonetics had a net margin of 2.37% and a return on equity of 17.33%. The firm had revenue of $259.77 million for the quarter, compared to analysts’ expectations of $265.40 million. During the same quarter in the prior year, the business earned $0.81 EPS. The business’s quarterly revenue was up 8.1% on a year-over-year basis.

A number of research firms have commented on HAE. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 27th. Morgan Stanley decreased their target price on shares of Haemonetics from $68.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Friday, January 7th. StockNews.com began coverage on shares of Haemonetics in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Barrington Research restated an “outperform” rating on shares of Haemonetics in a research note on Wednesday, February 9th. Finally, Raymond James decreased their target price on shares of Haemonetics from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 9th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has a consensus rating of “Buy” and a consensus price target of $71.67.

Hedge funds have recently bought and sold shares of the stock. Spire Wealth Management purchased a new position in shares of Haemonetics in the fourth quarter valued at $30,000. FourThought Financial LLC grew its holdings in shares of Haemonetics by 123.0% in the third quarter. FourThought Financial LLC now owns 921 shares of the medical instruments supplier’s stock valued at $65,000 after purchasing an additional 508 shares in the last quarter. Bbva USA grew its holdings in shares of Haemonetics by 161.7% in the third quarter. Bbva USA now owns 1,154 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 713 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Haemonetics by 29.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,902 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 436 shares in the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Haemonetics by 100.2% in the fourth quarter. Fifth Third Bancorp now owns 1,932 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 967 shares in the last quarter. 98.65% of the stock is owned by hedge funds and other institutional investors.

NYSE HAE traded down $0.05 on Monday, reaching $56.77. 312,570 shares of the stock were exchanged, compared to its average volume of 562,258. Haemonetics has a one year low of $43.50 and a one year high of $93.74. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of 132.03, a PEG ratio of 2.06 and a beta of 0.30. The firm’s 50-day moving average price is $57.84. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.05 and a quick ratio of 1.19.

Haemonetics Company Profile (Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Stories

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.